BIS outlines how pharmaceutical companies can seek company-specific onshoring agreements to reduce new 100% Section 232 tariffs on patented drugs and ingredients.
| less than a minute read
BIS Issues Procedures for Onshoring Agreements to Mitigate 100% Tariffs on Patented Pharmaceuticals
Get in touch
Get in touch
Get in touch
Get in touch
/Passle/6880addbd954bf894713d5af/SearchServiceImages/2026-05-15-14-07-35-662-6a0728a7c820d973200f9c91.jpg)
/Passle/6880addbd954bf894713d5af/SearchServiceImages/2026-05-15-13-22-06-727-6a071dfe157046f81d3498f2.jpg)
/Passle/6880addbd954bf894713d5af/SearchServiceImages/2026-05-15-13-20-16-115-6a071d90d144bbebfe1e190a.jpg)
/Passle/6880addbd954bf894713d5af/SearchServiceImages/2026-05-15-13-18-51-764-6a071d3b157046f81d3495d8.jpg)